Last reviewed · How we verify
TRC105 chimeric anti-CD105 antibody — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TRC105 chimeric anti-CD105 antibody (TRC105 chimeric anti-CD105 antibody) — Tracon Pharmaceuticals Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TRC105 chimeric anti-CD105 antibody TARGET | TRC105 chimeric anti-CD105 antibody | Tracon Pharmaceuticals Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TRC105 chimeric anti-CD105 antibody CI watch — RSS
- TRC105 chimeric anti-CD105 antibody CI watch — Atom
- TRC105 chimeric anti-CD105 antibody CI watch — JSON
- TRC105 chimeric anti-CD105 antibody alone — RSS
Cite this brief
Drug Landscape (2026). TRC105 chimeric anti-CD105 antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/trc105-chimeric-anti-cd105-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab